[{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Rexahn Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Rexahn","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Rexahn"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Oculos Development Services","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Oculos Development Services","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Oculos Development Services"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"American Society of Ophthalmic Administrator","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ American Society of Ophthalmic Administrator","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ American Society of Ophthalmic Administrator"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"FamyGen Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.050000000000000003,"dosageForm":"Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ FamyGen Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ FamyGen Life Sciences"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Ocuphire Pharma \/ Viatris"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ocuphire Pharma \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Phentolamine Mesylate
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
